Quantcast

Latest Michael Gnant Stories

2012-10-01 14:25:24

Two new studies presented at the ESMO 2012 Congress in Vienna, Austria show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy, but raise concerns about whether enough women are being offered these approaches. Prof Michael Gnant, a surgical oncologist from Vienna's Medical University, who was not involved in the studies, commented: "Clearly, advances in interdisciplinary preoperative approaches have contributed to...

2012-03-24 03:41:35

Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone. Professor Michael Gnant told the eighth European Breast Cancer Conference (EBCC-8) today (Friday) that the latest results from the BOLERO-2 trial would change clinical practice. "These results...

2011-12-07 21:34:36

Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression. Data from the Austrian Breast & Colorectal Cancer Study Group (ABCSG-12), reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011, confirmed and extended data reported at 48 months and 62 months of follow-up....

2010-06-05 07:27:00

EAST HANOVER, N.J., June 5 /PRNewswire/ -- New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, show that the addition of Zometa® (zoledronic acid) to first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12% (P=0.0179) compared with oral clodronate plus first-line chemotherapy(1). The 5.5...

7f45ffaa441f0c3e7683ba96796e754b
2008-06-02 15:29:29

In the first large study to affirm wider cancer-fighting applications for Zometa and other bone-building drugs called bisphosphonates, new research has found that Zometa, a bone loss prevention drug used by women undergoing breast cancer treatment, substantially reduced the risk of breast cancer recurrence.  The study, led by Dr. Michael Gnant of the Medical University of Vienna, was  reported Saturday at an American Society of Clinical Oncology conference in Chicago, and has given...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related